Oral formulation and suspension of an oncology drug
View Patent ↗Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
1. An oral suspension pharmaceutical composition, comprising 200 mg to 300 mg of sonidegib or a pharmaceutically acceptable salt thereof, a filler comprising microcrystalline cellulose, a glident comprising colloidal silicon dioxide, a lubricant comprising magnesium stearate, a flavor or sweetener and an oil wherein the oil comprises a medium chain fatty acid triglyceride comprising 55% triglycerides of C8 fatty acids and 45% triglycerides of C10 fatty acids.
2. The oral suspension pharmaceutical composition of claim 1 , wherein the flavor or sweetener is Tutti Frutti or sucralose.
3. The oral suspension pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 30 weight percent of sonidegib or a pharmaceutically acceptable salt thereof, about 68 weight percent of microcrystalline cellulose, about 0.5 weight percent of colloidal silicon dioxide, and about 0.5 weight percent of magnesium stearate, relative to the total weight of the sonidegib or a pharmaceutically acceptable salt thereof.
4. The oral suspension pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 300 mg of sonidegib, about 670 mg of microcrystalline cellulose, about 10 mg Tutti Frutti flavor, about 5 mg sucralose, about 5 mg anhydrous colloidal silicon dioxide, and about 10 mg magnesium stearate.
5. The oral suspension pharmaceutical suspension of claim 1 , wherein the amount of sonidegib is 200 mg.
6. An oral suspension pharmaceutical composition, comprising 200 mg to 300 mg of sonidegib or a pharmaceutically acceptable salt thereof, a filler comprising microcrystalline cellulose, a glident comprising colloidal silicon dioxide, a lubricant comprising magnesium stearate, a flavor or sweetener and an oil wherein the oil comprises a medium chain fatty acid triglyceride comprising 55% triglycerides of C8 fatty acids, 42% triglycerides of C10 fatty acids, 2% C6 fatty acids and 1% C12 fatty acids.